Aug 26 (Reuters) -

Dexcom ( DXCM ) said on Monday its over-the-counter

continuous glucose monitor, Stelo, is now available for use in

the United States at a price of up to $99.

Stelo was cleared by the U.S. health regulator in March for

use by adults aged 18 and older who do not use insulin, making

it the the first continuous glucose monitor available for

over-the-counter sales.

Patients could buy a pack of two sensors at a one-time

price of $99 or opt for a subscription to get a monthly delivery

for $89, Dexcom ( DXCM ) said.

In June, rival Abbott Laboratories ( ABT ) received the

regulator's clearance for two similar devices, Libre Rio and

Lingo, for adults with and without diabetes, respectively.

Abbott had said it plans to launch Lingo in the U.S.

this summer.

Lingo has been available in Britain since January for

120-150 pounds ($152-$190) per month.

Dexcom's ( DXCM ) Stelo uses a wearable sensor, paired with an

application on the user's smartphone or other smart device to

continuously measure blood glucose levels.

The device is not for individuals with problematic

hypoglycemia or low blood sugar as it is not designed to alert

the user about this potentially dangerous condition.